ConocoPhillips (COP) is a global integrated energy company. The Company’s business is organized into six segments: Exploration and Production (E&P), which explores for and produces oil, natural gas and natural gas liquids around the world; Midstream, which gathers, processes, and markets natural gas; and fractionates and markets natural gas liquids in the United States and Trinidad; Refining and Marketing (R&M), which purchases, refines, markets, and transports crude oil and petroleum products, including gasoline, distillates and aviation fuels; LUKOIL Investment, which consists of 20% interest in OAO LUKOIL, an international integrated oil and gas company; Chemicals, which manufactures and markets petrochemicals and plastics.; and Emerging Businesses, which engages in the developments of new technologies and businesses.

As of December 2008, the Company had exploration operations in 18 countries and production in 14 countries; worldwide refining capacity of 2.67 million BPD; and 63 natural gas processing plants and approximately 60,000 miles of gathering lines. As of the same period last year, its 50%-owned Chevron Phillips Chemical Company LLC (CPChem) had five research and technology centers and 35 production facilities in nine countries.

Founded in 1917, COP is based in Houston, Texas, with additional offices in Belle Chasse and Westlake, Louisiana.

Source: Reuters.com, SEC Filings, FY ending December

Shares of COP were driven lower Wednesday after the Company reported a 71% decline in third-quarter profit, attributable to lower commodity prices and declining refining margins. In its earnings report, the Company said it earned $1.5 billion, or $1.00 a share in the third-quarter. Meanwhile, it reported a 5% year to date increase in its E&P production, with international crude oil projects adding approximately 130,000 BOE per day. According to the Company, this partially offset the decline in earnings, along with cost reduction benefits of more than $0.4 billion after-tax across the Company.

“Although we operated well, we were adversely impacted by low North American natural gas prices and worldwide refining margins, which led us to curtail approximately 300 MMCFD of natural gas production starting in late August and reduce refinery runs,” COP CEO Jim Mulva stated in the Company’s press release. “During the quarter, R&M returned to positive earnings, and both R&M and Chemicals continue to benefit from low utility costs. In addition, for the third consecutive quarter, our operating costs were down compared with 2008, and our full-year cost reduction target of $1.4 billion has been achieved.”

Bollinger Bands

COP is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

MACD

COP’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9day moving average or signal line. This suggests that positive momentum has begun to slow.

Source: http://www.scottrade.com

GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. Together with its subsidiaries, GSK engages in the creation, discovery, development, manufacture and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. Its operations are organized in two segments: Pharmaceutical, which offers prescription medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology, emesis and dermatology; and Consumer Healthcare, which offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips, Tums, Citrucel, Contac and FiberChoice.

The Company operates in the United States, Europe, Japan, the Asia Pacific, the Middle East, Latin America, Africa and Canada.

Founded in 1935, GSK is based in Brentford, the United Kingdom.

Source: Reuters.com, SEC Filings, FY ending December

Boosted by strong sales of its flu drug Relenza, GSK reported by an 11% increase in its third quarter earnings. On Wednesday, GSK announced a net profit of 1.44 billion pounds for the quarter, while revenue rose 15% to 6.76 billion pounds. Analysts were looking for a profit of 1.19 billion pounds on sales of 6.76 billion pounds, according to data compiled by Dow Jones Newswires. GSK CEO Andrew Witty stated that the Company’s third-quarter performance reinforces its expectations of an improved performance in the second half of 2009.

Looking forward to Q4, the Company expects to get a further boost from its swine flu vaccines. According Witty, the consensus forecast that the company will make approximately 1 billion pounds in sales of H1N1 vaccines in Q4 is fairly accurate.

“We continue to have government express an interest and signing contracts with us and we anticipated that will continue for some time to come, although the lion’s share is probably passed,” Witty said in a conference call with investors.

Moving Average

GSK’s recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, GSK is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

MACD

GSK’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9day moving average or signal line. This suggests that positive momentum has begun to slow.

Bollinger Bands

GSK is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

Source: http://www.scottrade.com

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.